Monday, April 16, 2007

 

Position Updates: ARWR

Via Briefing:

7:04AM Arrowhead Research: Calando Pharma announces preclinical efficacy and safety data of targeted, systemic delivery of siRNA at AACR meeting (ARWR) 5.30 : Calando Pharmaceuticals, a majority-owned subsidiary of ARWR, announces it presented positive results of preclinical efficacy testing in mice using multiple, systemic dosing with Calando's lead siRNA therapeutic candidate CALAA-01, a nanoparticle containing non-chemically modified siRNA and a transferrin protein targeting agent at the American Association for Cancer Research (AACR) annual meeting on April 17, 2007 in Los Angeles, California.

Comments:
Nice fucking call.
 
Thanks yet again on ARWR Broker!
Enjoying IIG as well as well as all the others. Unbelieveable.

Christmas never seems to end at Fly on WallStreet.
 
Well played.

BTW, I've only been following your blog for a couple of weeks. Do you give sell recs as well as buys?

-DT
 
Broker do you think ARWR has more left in it? Or is it too late to get in on it?
 
Broker were you struck by lightning as a kid and now you can see the future?
 
Did Ducati vote for himself?
 
Fuck blogging, I don't feel like starting over!

I'm thinking of selling my site to shortdabull in exchange for some more MVIS shares.
 
BWLD shorts are getting their arms ripped off. MVIS shorts are about to get squeezed. Broker is off supervising Mexicans damming up his house from water, all the while counting his fucking money. What else could be better?
 
Mr. Cajun, I released TraderCaddy this morning, you can post at GS if you wish.
 
send me an invite
 
ARWR will head to 8 book it.
 
Post a Comment



<< Home

This page is powered by Blogger. Isn't yours?

 Subscribe in a reader

DISCLAIMER: This is a personal web site, reflecting the opinions of its author. It is not a production of my employer, and it is unaffiliated with any FINRA broker/dealer. Statements on this site do not represent the views or policies of anyone other than myself. The information on this site is provided for discussion purposes only, and are not investing recommendations. Under no circumstances does this information represent a recommendation to buy or sell securities.